GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Renalyx will continue operating as an independent unit within the group
The fresh capital will propel Cordance into its first-in-human clinical trial
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Subscribe To Our Newsletter & Stay Updated
